ACP Journal Club. Apixaban reduced stroke or systemic embolism in AF more than warfarin regardless of type or duration of AF.

Patients: 18 201 patients (median age 70 y, 65% men) who had AF or atrial flutter and ≥ 1 of the following: age ≥ 75 years; previous stroke, systemic embolism, or transient ischemic attack; symptomatic heart failure within 3 months or left ventricular ejection fraction ≤ 40%; diabetes mellitus; or hypertension. Exclusion criteria included AF due to a reversible cause; moderate or severe mitral stenosis; other indication for anticoagulation; or uncontrolled hypertension. Patients with AF for > 30 years were excluded from the subgroup analysis.